Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital Opens a Stake in Celsus, Another Biotech Company Today

Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY). According to a SEC filing, Broadfin purchased around 3.5 million shares of Celsus, which represents an 8.9% position in the company. At the current price of Celsus’s stock, the value of Broadfin’s position in the company amounts to over $14 million. Earlier today, Broadfin Capital also disclosed initiating a stake in another biopharmaceutical company, Idera Pharmaceuticals.


Celsus Therapeutics recently entered into a securities purchasing agreement, which will bring the company gross proceeds worth some $12.5 million. Under the agreement, Celsus sold around 22 million ordinary shares at a price of $0.57 apiece to a group of unnamed institutional healthcare investors. Celsus Therapeutics is a clinical stage company engaged in the development of a new type of anti-inflamatory drugs.

Disclosure: none

Recommended Reading:

Kevin Kotler’s Broadfin Capital Joins HealthCor in Idera

Phil Frohlich’s Prescott Group Is Buying More China Marine Food Stock

Columbia Wanger Asset Management Loves Boingo Wireless, Closes Out on This Trio